| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2966374 | Journal of Clinical Lipidology | 2010 | 9 Pages |
Abstract
The favorable safety and tolerability profile of ERN/LRPT for up to 1 year supports the use of LRPT to achieve improved therapeutic dosing of niacin, an agent with comprehensive lipid-modifying efficacy and shown to reduce cardiovascular risk.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
James PharmD, Harold MD, Michael MD, FACC, Christie M. MD, John F. MD, PhD, Yale MD, Abigaile BS, Olga PhD, Aditi PhD, Christine McCrary BS, Darbie PhD,